211 related articles for article (PubMed ID: 15986188)
1. Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.
Loiseau F; Le Bihan C; Hamon M; Thiébot MH
Psychopharmacology (Berl); 2005 Oct; 182(1):24-32. PubMed ID: 15986188
[TBL] [Abstract][Full Text] [Related]
2. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
Bourin M; Prica C
Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.
Bertaina-Anglade V; la Rochelle CD; Boyer PA; Mocaër E
Behav Pharmacol; 2006 Dec; 17(8):703-13. PubMed ID: 17110796
[TBL] [Abstract][Full Text] [Related]
4. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
5. Mouse psychosocial stress reduces motivation and cognitive function in operant reward tests: A model for reward pathology with effects of agomelatine.
Bergamini G; Cathomas F; Auer S; Sigrist H; Seifritz E; Patterson M; Gabriel C; Pryce CR
Eur Neuropsychopharmacol; 2016 Sep; 26(9):1448-1464. PubMed ID: 27422761
[TBL] [Abstract][Full Text] [Related]
6. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test.
Chenu F; Guiard BP; Bourin M; Gardier AM
Behav Brain Res; 2006 Sep; 172(2):256-63. PubMed ID: 16806519
[TBL] [Abstract][Full Text] [Related]
8. Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Vengeliene V; Noori HR; Spanagel R
Neuropsychopharmacology; 2015 Dec; 40(13):2897-906. PubMed ID: 25994077
[TBL] [Abstract][Full Text] [Related]
9. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
Fuchs E; Simon M; Schmelting B
Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S17-20. PubMed ID: 16436935
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1 ) receptor in assays for antidepressant and anxiolytic drugs.
Rupniak NM; Carlson EJ; Webb JK; Harrison T; Porsolt RD; Roux S; de Felipe C; Hunt SP; Oates B; Wheeldon A
Behav Pharmacol; 2001 Nov; 12(6-7):497-508. PubMed ID: 11742144
[TBL] [Abstract][Full Text] [Related]
12. Effects of imipramine-like drugs and serotonin uptake blockers on delay of reward in rats. Possible implication in the behavioral mechanism of action of antidepressants.
Bizot JC; Thiébot MH; Le Bihan C; Soubrié P; Simon P
J Pharmacol Exp Ther; 1988 Sep; 246(3):1144-51. PubMed ID: 3418513
[TBL] [Abstract][Full Text] [Related]
13. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Millan MJ; Brocco M; Gobert A; Dekeyne A
Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999
[TBL] [Abstract][Full Text] [Related]
14. GW117: A novel serotonin (5-HT
Gao N; Zheng W; Murezati T; Gu W; Li X; Jin Z
CNS Neurosci Ther; 2021 Jun; 27(6):702-713. PubMed ID: 33650297
[TBL] [Abstract][Full Text] [Related]
15. Serotonin and tolerance to delay of reward in rats.
Bizot J; Le Bihan C; Puech AJ; Hamon M; Thiébot M
Psychopharmacology (Berl); 1999 Oct; 146(4):400-12. PubMed ID: 10550490
[TBL] [Abstract][Full Text] [Related]
16. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
Guardiola-Lemaitre B; De Bodinat C; Delagrange P; Millan MJ; Munoz C; Mocaër E
Br J Pharmacol; 2014 Aug; 171(15):3604-19. PubMed ID: 24724693
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
[TBL] [Abstract][Full Text] [Related]
19. Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states.
Ochoa-Sanchez R; Comai S; Spadoni G; Bedini A; Tarzia G; Gobbi G
Neurosci Lett; 2014 Feb; 561():156-61. PubMed ID: 24406151
[TBL] [Abstract][Full Text] [Related]
20. Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam.
Bhutada P; Dixit P; Thakur K; Deshmukh P; Kaulaskar S
Kaohsiung J Med Sci; 2013 Jul; 29(7):362-7. PubMed ID: 23768699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
